|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
15000 West 6th Avenue, Suite 400, Golden, CO 80401, US
|
|
At Theralink Technologies, our approach is based on more than 16 years of research and development. Our research indicates that genomic and transcriptomic information alone provides an incomplete information resource for physicians to make patient-specific treatment decisions.
Our phosphoproteomic RPPA approach is the only commercial platform that quantifies the activation state (phosphorylation) of drug target proteins and their downstream signaling partners within the tumor tissue.
Our advanced technology exploits our understanding of the drug-receptor and drug-protein interactions that drive treatment responses. The Theralink assay has been developed to provide physicians with a treatment decision support tool to assist in selecting therapies that are more likely to result in responses to treatment.
Our large panel of new protein biomarkers targets therapeutic molecular inhibitors including current FDA approved therapies and certain investigational drugs, making Theralink® an invaluable tool for oncologists and biopharma clinical trials.
|
Theralink Technologies, Inc. Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Theralink Technologies, Inc. email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Theralink Technologies, Inc. customer service number call here 888-585-4923. To contact Theralink Technologies, Inc. customer service number in your country click here to find.
Mick Ruxin is the CEO of Theralink Technologies, Inc.. To contact Mick Ruxin email at [email protected]. Or you may call +1.3142295638 or +1.3038985896
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.